University Of Colorado Hospital

Recent phase 3 trials KEYNOTE-412 and JAVELIN Head and Neck 100 failed to show survival benefits when adding immunotherapy to chemoradiotherapy in locally advanced head and neck cancer, prompting researchers to investigate alternative treatment sequences.

Stereotactic ablative radiotherapy demonstrates effective local control for primary renal cell carcinoma, with a 5-year local failure rate of only 5.5%.